# Germany cannabis policy: health impact, coverage cuts

> Live situation record from CLSTR: https://clstr.news/situations/germany-cannabis-policy-health-effects
> Updated: 2026-07-29T21:44:53.000Z. Sources: 13. Developments: 2.

Two years after Germany partially legalized adult possession and cultivation of cannabis in 2024, researchers examined over 70,000 hospital admissions and identified a moderate rise—about 7 %—in cannabis‑related acute poisonings and psychosis cases. The increase was linked to higher‑potency medical cannabis made more accessible after the drug was removed from the Narcotics Act, rather than to illegal street trade.

In July 2026 the government further tightened medical‑cannabis rules by stripping dried cannabis flower from statutory health‑insurance coverage and mandating a six‑month trial of an approved finished medicine before any extract, dronabinol or nabilone can be prescribed. The change, affecting roughly 65,000 patients, provoked constitutional complaints from patient organisations such as the Bund Deutscher Cannabis‑Patienten, which argue that the measures impose an undue burden on seriously ill individuals.

National monitoring data released at the end of July 2026 showed that outpatient episodes for cannabis‑use disorder fell by about 15 % in 2024 compared with 2023, with the sharpest drops among people under 25 and male patients. Analysts suggest the decline may reflect fewer referrals from police and courts rather than a genuine reduction in prevalence. Patient groups, including the Bundesverband Cannabis Wirtschaft and the Bundesverband pharmazeutischer Cannabinoid‑unternehmen, have joined the legal challenges, maintaining pressure on the government to preserve access to medical cannabis.

## Claims

- Outpatient care episodes for cannabis‑use disorder declined by 15% in Germany in 2024 compared with 2023. (corroborated by 2 sources)
- Male cannabis‑use disorder admissions dropped from 23.9 to 19.8 per facility between 2023 and 2024; female admissions stayed around 5.5 per facility. (corroborated by 2 sources)
- The German Cannabis Act (CanG) legalised adult‑use cannabis in April 2024. (corroborated by 2 sources)
- Effective 30 July 2026, statutory health‑insurance reimbursement for cannabis flower was removed in Germany, affecting about 65,000 patients. (corroborated by 2 sources)
- Extracts and approved cannabis pharmaceuticals remain reimbursable only after a mandatory six‑month trial of a licensed product. (corroborated by 2 sources)
- Among people under 25, cannabis‑use disorder admissions fell by about 24% in 2024. (single source)
- Patient groups (Bundesverband Cannabis Wirtschaft, Bundesverband pharmazeutischer Cannabinoidunternehmen, Bund Deutscher Cannabis‑Patienten) have filed legal challenges against the insurance cut, deem (single source)
- Since 1 April 2024, adults in Germany may privately cultivate up to three cannabis plants, with possession limits of 50 g at home and 25 g while travelling. (single source)

## Timeline

### 2026-07-29: Germany reports decline in cannabis addiction treatment and new limits on medical cannabis coverage

Germany’s 2024 cannabis legalisation cut addiction‑treatment admissions by 15%, while a 2026 law ends insurance coverage for cannabis flower, affecting 65,000 patients and prompting legal challenges.

6 sources. https://clstr.news/cluster/germanys-medical-cannabis-insurance-ban-triggers-patient-lawsuits

### 2026-07-22: Germany sees rise in hospital admissions after cannabis legalization

German cannabis legalization led to a moderate 7 % rise in hospital admissions for poisonings and psychoses, likely due to higher‑THC medical cannabis.

7 sources. https://clstr.news/cluster/germany-sees-rise-in-cannabisrelated-hospital-admissions

---
Cite as: Germany cannabis policy: health impact, coverage cuts. CLSTR, https://clstr.news/situations/germany-cannabis-policy-health-effects